United Therapeutics is pioneering a new frontier in organ transplants using pig kidneys. STORY HIGHLIGHTS FDA clears United Therapeutics for human trials of pig-to-human kidney transplants.

It's as significant for the medical community as it is for the local business. From the Washington Business Journal. United Therapeutics Corp. (NASDAQ: UTHR) has scored a regulatory green light to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Protagonist Therapeutics (PTGX – Research Report). The company’s shares closed yesterday at ...

Citi analyst David Lebowitz initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $38 price target Viking’s VK2735 is an “intriguing potential blockbuster,” with its GLP ...

Another biotech company, United Therapeutics, announced this week that it had received the green light from the FDA to move forward with a xenotransplant trial with its pig kidneys, which have 10 ...

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of unique products to address the unmet medical needs of patients with chronic ...

SEC Filings provided by EDGAR Online, Inc.